 | • レポートコード：GIR-107A15083 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、組換えエリスロポエチンのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。組換えエリスロポエチンの種類別市場規模（rhEPO、赤血球生成刺激剤（ESA））、用途別市場規模（慢性腎臓病、がん関連貧血、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・組換えエリスロポエチンの市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Amgen、Johnson & Johnson、Kyowa Hakko Kirin、Roche、3SBio Group、Celltrion, Inc、Teva Pharmaceutical Industries Ltd、F. Hoffmann-La Roche Ltd、LG Life Sciences Ltd、Biocon Limited、Intas Pharmaceuticals Ltd、Sun Pharmaceutical Industries Ltd、Dr. Reddy's Laboratories Ltd ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：rhEPO、赤血球生成刺激剤（ESA） ・用途別分析2016年-2026年：慢性腎臓病、がん関連貧血、その他 ・組換えエリスロポエチンの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・組換えエリスロポエチンのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・組換えエリスロポエチンのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・組換えエリスロポエチンの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・組換えエリスロポエチンの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Recombinant Erythropoietin market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Recombinant Erythropoietin size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Recombinant Erythropoietin market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Recombinant Erythropoietin market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
rhEPO
Erythropoiesis-Stimulating Agents (ESA)
Market segment by Application, can be divided into
Chronic Kidney Disease
Cancer Related Anemia
Others
Market segment by players, this report covers
Amgen
Johnson & Johnson
Kyowa Hakko Kirin
Roche
3SBio Group
Celltrion, Inc
Teva Pharmaceutical Industries Ltd
F. Hoffmann-La Roche Ltd
LG Life Sciences Ltd
Biocon Limited
Intas Pharmaceuticals Ltd
Sun Pharmaceutical Industries Ltd
Dr. Reddy’s Laboratories Ltd
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Recombinant Erythropoietin product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Recombinant Erythropoietin, with revenue, gross margin and global market share of Recombinant Erythropoietin from 2019 to 2021.
Chapter 3, the Recombinant Erythropoietin competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Recombinant Erythropoietin market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Recombinant Erythropoietin research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Recombinant Erythropoietin
1.2 Classification of Recombinant Erythropoietin by Type
1.2.1 Overview: Global Recombinant Erythropoietin Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Recombinant Erythropoietin Revenue Market Share by Type in 2020
1.2.3 rhEPO
1.2.4 Erythropoiesis-Stimulating Agents (ESA)
1.3 Global Recombinant Erythropoietin Market by Application
1.3.1 Overview: Global Recombinant Erythropoietin Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Chronic Kidney Disease
1.3.3 Cancer Related Anemia
1.3.4 Others
1.4 Global Recombinant Erythropoietin Market Size & Forecast
1.5 Global Recombinant Erythropoietin Market Size and Forecast by Region
1.5.1 Global Recombinant Erythropoietin Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Recombinant Erythropoietin Market Size by Region, (2016-2021)
1.5.3 North America Recombinant Erythropoietin Market Size and Prospect (2016-2026)
1.5.4 Europe Recombinant Erythropoietin Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Recombinant Erythropoietin Market Size and Prospect (2016-2026)
1.5.6 South America Recombinant Erythropoietin Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Recombinant Erythropoietin Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Recombinant Erythropoietin Market Drivers
1.6.2 Recombinant Erythropoietin Market Restraints
1.6.3 Recombinant Erythropoietin Trends Analysis
2 Company Profiles
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen Recombinant Erythropoietin Product and Solutions
2.1.4 Amgen Recombinant Erythropoietin Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Amgen Recent Developments and Future Plans
2.2 Johnson & Johnson
2.2.1 Johnson & Johnson Details
2.2.2 Johnson & Johnson Major Business
2.2.3 Johnson & Johnson Recombinant Erythropoietin Product and Solutions
2.2.4 Johnson & Johnson Recombinant Erythropoietin Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Johnson & Johnson Recent Developments and Future Plans
2.3 Kyowa Hakko Kirin
2.3.1 Kyowa Hakko Kirin Details
2.3.2 Kyowa Hakko Kirin Major Business
2.3.3 Kyowa Hakko Kirin Recombinant Erythropoietin Product and Solutions
2.3.4 Kyowa Hakko Kirin Recombinant Erythropoietin Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Kyowa Hakko Kirin Recent Developments and Future Plans
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business
2.4.3 Roche Recombinant Erythropoietin Product and Solutions
2.4.4 Roche Recombinant Erythropoietin Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Roche Recent Developments and Future Plans
2.5 3SBio Group
2.5.1 3SBio Group Details
2.5.2 3SBio Group Major Business
2.5.3 3SBio Group Recombinant Erythropoietin Product and Solutions
2.5.4 3SBio Group Recombinant Erythropoietin Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 3SBio Group Recent Developments and Future Plans
2.6 Celltrion, Inc
2.6.1 Celltrion, Inc Details
2.6.2 Celltrion, Inc Major Business
2.6.3 Celltrion, Inc Recombinant Erythropoietin Product and Solutions
2.6.4 Celltrion, Inc Recombinant Erythropoietin Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Celltrion, Inc Recent Developments and Future Plans
2.7 Teva Pharmaceutical Industries Ltd
2.7.1 Teva Pharmaceutical Industries Ltd Details
2.7.2 Teva Pharmaceutical Industries Ltd Major Business
2.7.3 Teva Pharmaceutical Industries Ltd Recombinant Erythropoietin Product and Solutions
2.7.4 Teva Pharmaceutical Industries Ltd Recombinant Erythropoietin Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
2.8 F. Hoffmann-La Roche Ltd
2.8.1 F. Hoffmann-La Roche Ltd Details
2.8.2 F. Hoffmann-La Roche Ltd Major Business
2.8.3 F. Hoffmann-La Roche Ltd Recombinant Erythropoietin Product and Solutions
2.8.4 F. Hoffmann-La Roche Ltd Recombinant Erythropoietin Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
2.9 LG Life Sciences Ltd
2.9.1 LG Life Sciences Ltd Details
2.9.2 LG Life Sciences Ltd Major Business
2.9.3 LG Life Sciences Ltd Recombinant Erythropoietin Product and Solutions
2.9.4 LG Life Sciences Ltd Recombinant Erythropoietin Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 LG Life Sciences Ltd Recent Developments and Future Plans
2.10 Biocon Limited
2.10.1 Biocon Limited Details
2.10.2 Biocon Limited Major Business
2.10.3 Biocon Limited Recombinant Erythropoietin Product and Solutions
2.10.4 Biocon Limited Recombinant Erythropoietin Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Biocon Limited Recent Developments and Future Plans
2.11 Intas Pharmaceuticals Ltd
2.11.1 Intas Pharmaceuticals Ltd Details
2.11.2 Intas Pharmaceuticals Ltd Major Business
2.11.3 Intas Pharmaceuticals Ltd Recombinant Erythropoietin Product and Solutions
2.11.4 Intas Pharmaceuticals Ltd Recombinant Erythropoietin Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Intas Pharmaceuticals Ltd Recent Developments and Future Plans
2.12 Sun Pharmaceutical Industries Ltd
2.12.1 Sun Pharmaceutical Industries Ltd Details
2.12.2 Sun Pharmaceutical Industries Ltd Major Business
2.12.3 Sun Pharmaceutical Industries Ltd Recombinant Erythropoietin Product and Solutions
2.12.4 Sun Pharmaceutical Industries Ltd Recombinant Erythropoietin Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Sun Pharmaceutical Industries Ltd Recent Developments and Future Plans
2.13 Dr. Reddy’s Laboratories Ltd
2.13.1 Dr. Reddy’s Laboratories Ltd Details
2.13.2 Dr. Reddy’s Laboratories Ltd Major Business
2.13.3 Dr. Reddy’s Laboratories Ltd Recombinant Erythropoietin Product and Solutions
2.13.4 Dr. Reddy’s Laboratories Ltd Recombinant Erythropoietin Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Dr. Reddy’s Laboratories Ltd Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Recombinant Erythropoietin Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Recombinant Erythropoietin Players Market Share
3.2.2 Top 10 Recombinant Erythropoietin Players Market Share
3.2.3 Market Competition Trend
3.3 Recombinant Erythropoietin Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Recombinant Erythropoietin Revenue and Market Share by Type (2016-2021)
4.2 Global Recombinant Erythropoietin Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Recombinant Erythropoietin Revenue Market Share by Application (2016-2021)
5.2 Recombinant Erythropoietin Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Recombinant Erythropoietin Revenue by Type (2016-2026)
6.2 North America Recombinant Erythropoietin Revenue by Application (2016-2026)
6.3 North America Recombinant Erythropoietin Market Size by Country
6.3.1 North America Recombinant Erythropoietin Revenue by Country (2016-2026)
6.3.2 United States Recombinant Erythropoietin Market Size and Forecast (2016-2026)
6.3.3 Canada Recombinant Erythropoietin Market Size and Forecast (2016-2026)
6.3.4 Mexico Recombinant Erythropoietin Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Recombinant Erythropoietin Revenue by Type (2016-2026)
7.2 Europe Recombinant Erythropoietin Revenue by Application (2016-2026)
7.3 Europe Recombinant Erythropoietin Market Size by Country
7.3.1 Europe Recombinant Erythropoietin Revenue by Country (2016-2026)
7.3.2 Germany Recombinant Erythropoietin Market Size and Forecast (2016-2026)
7.3.3 France Recombinant Erythropoietin Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Recombinant Erythropoietin Market Size and Forecast (2016-2026)
7.3.5 Russia Recombinant Erythropoietin Market Size and Forecast (2016-2026)
7.3.6 Italy Recombinant Erythropoietin Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Recombinant Erythropoietin Revenue by Type (2016-2026)
8.2 Asia-Pacific Recombinant Erythropoietin Revenue by Application (2016-2026)
8.3 Asia-Pacific Recombinant Erythropoietin Market Size by Region
8.3.1 Asia-Pacific Recombinant Erythropoietin Revenue by Region (2016-2026)
8.3.2 China Recombinant Erythropoietin Market Size and Forecast (2016-2026)
8.3.3 Japan Recombinant Erythropoietin Market Size and Forecast (2016-2026)
8.3.4 South Korea Recombinant Erythropoietin Market Size and Forecast (2016-2026)
8.3.5 India Recombinant Erythropoietin Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Recombinant Erythropoietin Market Size and Forecast (2016-2026)
8.3.7 Australia Recombinant Erythropoietin Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Recombinant Erythropoietin Revenue by Type (2016-2026)
9.2 South America Recombinant Erythropoietin Revenue by Application (2016-2026)
9.3 South America Recombinant Erythropoietin Market Size by Country
9.3.1 South America Recombinant Erythropoietin Revenue by Country (2016-2026)
9.3.2 Brazil Recombinant Erythropoietin Market Size and Forecast (2016-2026)
9.3.3 Argentina Recombinant Erythropoietin Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Recombinant Erythropoietin Revenue by Type (2016-2026)
10.2 Middle East & Africa Recombinant Erythropoietin Revenue by Application (2016-2026)
10.3 Middle East & Africa Recombinant Erythropoietin Market Size by Country
10.3.1 Middle East & Africa Recombinant Erythropoietin Revenue by Country (2016-2026)
10.3.2 Turkey Recombinant Erythropoietin Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Recombinant Erythropoietin Market Size and Forecast (2016-2026)
10.3.4 UAE Recombinant Erythropoietin Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Recombinant Erythropoietin Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Recombinant Erythropoietin Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Recombinant Erythropoietin Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Recombinant Erythropoietin Revenue (USD Million) by Region (2016-2021)
Table 5. Global Recombinant Erythropoietin Revenue Market Share by Region (2021-2026)
Table 6. Amgen Corporate Information, Head Office, and Major Competitors
Table 7. Amgen Major Business
Table 8. Amgen Recombinant Erythropoietin Product and Solutions
Table 9. Amgen Recombinant Erythropoietin Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 11. Johnson & Johnson Major Business
Table 12. Johnson & Johnson Recombinant Erythropoietin Product and Solutions
Table 13. Johnson & Johnson Recombinant Erythropoietin Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Kyowa Hakko Kirin Corporate Information, Head Office, and Major Competitors
Table 15. Kyowa Hakko Kirin Major Business
Table 16. Kyowa Hakko Kirin Recombinant Erythropoietin Product and Solutions
Table 17. Kyowa Hakko Kirin Recombinant Erythropoietin Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Roche Corporate Information, Head Office, and Major Competitors
Table 19. Roche Major Business
Table 20. Roche Recombinant Erythropoietin Product and Solutions
Table 21. Roche Recombinant Erythropoietin Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. 3SBio Group Corporate Information, Head Office, and Major Competitors
Table 23. 3SBio Group Major Business
Table 24. 3SBio Group Recombinant Erythropoietin Product and Solutions
Table 25. 3SBio Group Recombinant Erythropoietin Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Celltrion, Inc Corporate Information, Head Office, and Major Competitors
Table 27. Celltrion, Inc Major Business
Table 28. Celltrion, Inc Recombinant Erythropoietin Product and Solutions
Table 29. Celltrion, Inc Recombinant Erythropoietin Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Teva Pharmaceutical Industries Ltd Corporate Information, Head Office, and Major Competitors
Table 31. Teva Pharmaceutical Industries Ltd Major Business
Table 32. Teva Pharmaceutical Industries Ltd Recombinant Erythropoietin Product and Solutions
Table 33. Teva Pharmaceutical Industries Ltd Recombinant Erythropoietin Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. F. Hoffmann-La Roche Ltd Corporate Information, Head Office, and Major Competitors
Table 35. F. Hoffmann-La Roche Ltd Major Business
Table 36. F. Hoffmann-La Roche Ltd Recombinant Erythropoietin Product and Solutions
Table 37. F. Hoffmann-La Roche Ltd Recombinant Erythropoietin Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. LG Life Sciences Ltd Corporate Information, Head Office, and Major Competitors
Table 39. LG Life Sciences Ltd Major Business
Table 40. LG Life Sciences Ltd Recombinant Erythropoietin Product and Solutions
Table 41. LG Life Sciences Ltd Recombinant Erythropoietin Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Biocon Limited Corporate Information, Head Office, and Major Competitors
Table 43. Biocon Limited Major Business
Table 44. Biocon Limited Recombinant Erythropoietin Product and Solutions
Table 45. Biocon Limited Recombinant Erythropoietin Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Intas Pharmaceuticals Ltd Corporate Information, Head Office, and Major Competitors
Table 47. Intas Pharmaceuticals Ltd Major Business
Table 48. Intas Pharmaceuticals Ltd Recombinant Erythropoietin Product and Solutions
Table 49. Intas Pharmaceuticals Ltd Recombinant Erythropoietin Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Sun Pharmaceutical Industries Ltd Corporate Information, Head Office, and Major Competitors
Table 51. Sun Pharmaceutical Industries Ltd Major Business
Table 52. Sun Pharmaceutical Industries Ltd Recombinant Erythropoietin Product and Solutions
Table 53. Sun Pharmaceutical Industries Ltd Recombinant Erythropoietin Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Dr. Reddy's Laboratories Ltd Corporate Information, Head Office, and Major Competitors
Table 55. Dr. Reddy's Laboratories Ltd Major Business
Table 56. Dr. Reddy's Laboratories Ltd Recombinant Erythropoietin Product and Solutions
Table 57. Dr. Reddy's Laboratories Ltd Recombinant Erythropoietin Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Global Recombinant Erythropoietin Revenue (USD Million) by Players (2019-2021)
Table 59. Global Recombinant Erythropoietin Revenue Share by Players (2019-2021)
Table 60. Breakdown of Recombinant Erythropoietin by Company Type (Tier 1, Tier 2 and Tier 3)
Table 61. Recombinant Erythropoietin Players Head Office, Products and Services Provided
Table 62. Recombinant Erythropoietin Mergers & Acquisitions in the Past Five Years
Table 63. Recombinant Erythropoietin New Entrants and Expansion Plans
Table 64. Global Recombinant Erythropoietin Revenue (USD Million) by Type (2016-2021)
Table 65. Global Recombinant Erythropoietin Revenue Share by Type (2016-2021)
Table 66. Global Recombinant Erythropoietin Revenue Forecast by Type (2021-2026)
Table 67. Global Recombinant Erythropoietin Revenue by Application (2016-2021)
Table 68. Global Recombinant Erythropoietin Revenue Forecast by Application (2021-2026)
Table 69. North America Recombinant Erythropoietin Revenue by Type (2016-2021) & (USD Million)
Table 70. North America Recombinant Erythropoietin Revenue by Type (2021-2026) & (USD Million)
Table 71. North America Recombinant Erythropoietin Revenue by Application (2016-2021) & (USD Million)
Table 72. North America Recombinant Erythropoietin Revenue by Application (2021-2026) & (USD Million)
Table 73. North America Recombinant Erythropoietin Revenue by Country (2016-2021) & (USD Million)
Table 74. North America Recombinant Erythropoietin Revenue by Country (2021-2026) & (USD Million)
Table 75. Europe Recombinant Erythropoietin Revenue by Type (2016-2021) & (USD Million)
Table 76. Europe Recombinant Erythropoietin Revenue by Type (2021-2026) & (USD Million)
Table 77. Europe Recombinant Erythropoietin Revenue by Application (2016-2021) & (USD Million)
Table 78. Europe Recombinant Erythropoietin Revenue by Application (2021-2026) & (USD Million)
Table 79. Europe Recombinant Erythropoietin Revenue by Country (2016-2021) & (USD Million)
Table 80. Europe Recombinant Erythropoietin Revenue by Country (2021-2026) & (USD Million)
Table 81. Asia-Pacific Recombinant Erythropoietin Revenue by Type (2016-2021) & (USD Million)
Table 82. Asia-Pacific Recombinant Erythropoietin Revenue by Type (2021-2026) & (USD Million)
Table 83. Asia-Pacific Recombinant Erythropoietin Revenue by Application (2016-2021) & (USD Million)
Table 84. Asia-Pacific Recombinant Erythropoietin Revenue by Application (2021-2026) & (USD Million)
Table 85. Asia-Pacific Recombinant Erythropoietin Revenue by Region (2016-2021) & (USD Million)
Table 86. Asia-Pacific Recombinant Erythropoietin Revenue by Region (2021-2026) & (USD Million)
Table 87. South America Recombinant Erythropoietin Revenue by Type (2016-2021) & (USD Million)
Table 88. South America Recombinant Erythropoietin Revenue by Type (2021-2026) & (USD Million)
Table 89. South America Recombinant Erythropoietin Revenue by Application (2016-2021) & (USD Million)
Table 90. South America Recombinant Erythropoietin Revenue by Application (2021-2026) & (USD Million)
Table 91. South America Recombinant Erythropoietin Revenue by Country (2016-2021) & (USD Million)
Table 92. South America Recombinant Erythropoietin Revenue by Country (2021-2026) & (USD Million)
Table 93. Middle East & Africa Recombinant Erythropoietin Revenue by Type (2016-2021) & (USD Million)
Table 94. Middle East & Africa Recombinant Erythropoietin Revenue by Type (2021-2026) & (USD Million)
Table 95. Middle East & Africa Recombinant Erythropoietin Revenue by Application (2016-2021) & (USD Million)
Table 96. Middle East & Africa Recombinant Erythropoietin Revenue by Application (2021-2026) & (USD Million)
Table 97. Middle East & Africa Recombinant Erythropoietin Revenue by Country (2016-2021) & (USD Million)
Table 98. Middle East & Africa Recombinant Erythropoietin Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Recombinant Erythropoietin Picture
Figure 2. Global Recombinant Erythropoietin Revenue Market Share by Type in 2020
Figure 3. rhEPO
Figure 4. Erythropoiesis-Stimulating Agents (ESA)
Figure 5. Recombinant Erythropoietin Revenue Market Share by Application in 2020
Figure 6. Chronic Kidney Disease Picture
Figure 7. Cancer Related Anemia Picture
Figure 8. Others Picture
Figure 9. Global Recombinant Erythropoietin Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Recombinant Erythropoietin Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Recombinant Erythropoietin Revenue Market Share by Region (2016-2026)
Figure 12. Global Recombinant Erythropoietin Revenue Market Share by Region in 2020
Figure 13. North America Recombinant Erythropoietin Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Recombinant Erythropoietin Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Recombinant Erythropoietin Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Recombinant Erythropoietin Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Middle East and Africa Recombinant Erythropoietin Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Recombinant Erythropoietin Market Drivers
Figure 19. Recombinant Erythropoietin Market Restraints
Figure 20. Recombinant Erythropoietin Market Trends
Figure 21. Amgen Recent Developments and Future Plans
Figure 22. Johnson & Johnson Recent Developments and Future Plans
Figure 23. Kyowa Hakko Kirin Recent Developments and Future Plans
Figure 24. Roche Recent Developments and Future Plans
Figure 25. 3SBio Group Recent Developments and Future Plans
Figure 26. Celltrion, Inc Recent Developments and Future Plans
Figure 27. Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
Figure 28. F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
Figure 29. LG Life Sciences Ltd Recent Developments and Future Plans
Figure 30. Biocon Limited Recent Developments and Future Plans
Figure 31. Intas Pharmaceuticals Ltd Recent Developments and Future Plans
Figure 32. Sun Pharmaceutical Industries Ltd Recent Developments and Future Plans
Figure 33. Dr. Reddy's Laboratories Ltd Recent Developments and Future Plans
Figure 34. Global Recombinant Erythropoietin Revenue Share by Players in 2020
Figure 35. Recombinant Erythropoietin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 36. Global Top 3 Players Recombinant Erythropoietin Revenue Market Share in 2020
Figure 37. Global Top 10 Players Recombinant Erythropoietin Revenue Market Share in 2020
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 39. Global Recombinant Erythropoietin Revenue Share by Type in 2020
Figure 40. Global Recombinant Erythropoietin Market Share Forecast by Type (2021-2026)
Figure 41. Global Recombinant Erythropoietin Revenue Share by Application in 2020
Figure 42. Global Recombinant Erythropoietin Market Share Forecast by Application (2021-2026)
Figure 43. North America Recombinant Erythropoietin Sales Market Share by Type (2016-2026)
Figure 44. North America Recombinant Erythropoietin Sales Market Share by Application (2016-2026)
Figure 45. North America Recombinant Erythropoietin Revenue Market Share by Country (2016-2026)
Figure 46. United States Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Canada Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Mexico Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Europe Recombinant Erythropoietin Sales Market Share by Type (2016-2026)
Figure 50. Europe Recombinant Erythropoietin Sales Market Share by Application (2016-2026)
Figure 51. Europe Recombinant Erythropoietin Revenue Market Share by Country (2016-2026)
Figure 52. Germany Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. France Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. United Kingdom Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Russia Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Italy Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Asia-Pacific Recombinant Erythropoietin Sales Market Share by Type (2016-2026)
Figure 58. Asia-Pacific Recombinant Erythropoietin Sales Market Share by Application (2016-2026)
Figure 59. Asia-Pacific Recombinant Erythropoietin Revenue Market Share by Region (2016-2026)
Figure 60. China Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South Korea Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Recombinant Erythropoietin Sales Market Share by Type (2016-2026)
Figure 67. South America Recombinant Erythropoietin Sales Market Share by Application (2016-2026)
Figure 68. South America Recombinant Erythropoietin Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East and Africa Recombinant Erythropoietin Sales Market Share by Type (2016-2026)
Figure 72. Middle East and Africa Recombinant Erythropoietin Sales Market Share by Application (2016-2026)
Figure 73. Middle East and Africa Recombinant Erythropoietin Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. UAE Recombinant Erythropoietin Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
世界の抗血友病因子（組換え）市場 2021：企業別、地域別、種類・用途別 The Antihemophilic Factor (Recombinant) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, t…- 組換えタンパク質市場：世界及び中国市場分析・予測（～2024年） Recombinant Proteins Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Recombinant Proteins industry with a focus on the Chinese market. The report provides key statistics on the market status of the Recombinant Proteins manufac…
- 組換えペプチド市場：世界及び中国市場分析・予測（～2024年） Recombinant Peptides Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Recombinant Peptides industry with a focus on the Chinese market. The report provides key statistics on the market status of the Recombinant Peptides manufac…
- 世界の組換え細胞培養サプリメント市場予測（～2024年） Recombinant proteins are increasingly being used as defined supplements in biopharmaceutical, vaccine and stem cell manufacturing. Scope of the Report: The global Recombinant Cell Culture Supplements market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 202…
- 世界の組換え血漿タンパク質市場予測（～2024年） For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation factors, anticoagulants, immunoglobulins, and albumin--essential to the treatment of serious congenital or acquired bleeding or immunological diseases…